ECSP11011033A - Virus sincitial respiratorio vivo atenuado - Google Patents

Virus sincitial respiratorio vivo atenuado

Info

Publication number
ECSP11011033A
ECSP11011033A EC2011011033A ECSP11011033A ECSP11011033A EC SP11011033 A ECSP11011033 A EC SP11011033A EC 2011011033 A EC2011011033 A EC 2011011033A EC SP11011033 A ECSP11011033 A EC SP11011033A EC SP11011033 A ECSP11011033 A EC SP11011033A
Authority
EC
Ecuador
Prior art keywords
rsv
attened
lived
synthetic virus
respiratory synthetic
Prior art date
Application number
EC2011011033A
Other languages
English (en)
Inventor
Xian Liang
Mary K Yagodich
Michael P Citron
Daniel J Distefano
David L Krah
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of ECSP11011033A publication Critical patent/ECSP11011033A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/115—Paramyxoviridae, e.g. parainfluenza virus
    • C07K14/135—Respiratory syncytial virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/544—Mucosal route to the airways
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18561—Methods of inactivation or attenuation
    • C12N2760/18564—Methods of inactivation or attenuation by serial passage

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

El presente invento divulga virus sincitiales respiratorios (VSR) vivos atenuados útiles como vacunas contra infecciones por VSR y/o el desarrollo de severas enfermedades asociadas con el VSR. Los virus divulgados están atenuados hasta el punto que no son patógenos al administrarse en un sujeto pero retienen de manera sustancial las propiedades antigénicas e inmunogénicas del VSR silvestre.
EC2011011033A 2008-11-05 2011-05-05 Virus sincitial respiratorio vivo atenuado ECSP11011033A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US19832708P 2008-11-05 2008-11-05

Publications (1)

Publication Number Publication Date
ECSP11011033A true ECSP11011033A (es) 2011-12-30

Family

ID=41527812

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2011011033A ECSP11011033A (es) 2008-11-05 2011-05-05 Virus sincitial respiratorio vivo atenuado

Country Status (19)

Country Link
US (1) US9011876B2 (es)
EP (1) EP2346990B1 (es)
JP (2) JP5016731B2 (es)
KR (1) KR20110063863A (es)
CN (1) CN102272295A (es)
AU (1) AU2009311287C1 (es)
BR (1) BRPI0921424A2 (es)
CA (1) CA2742086A1 (es)
CL (1) CL2011000999A1 (es)
CO (1) CO6362047A2 (es)
EC (1) ECSP11011033A (es)
IL (1) IL212437A0 (es)
MA (1) MA32878B1 (es)
MX (1) MX2011004719A (es)
PE (1) PE20110394A1 (es)
RU (1) RU2011122615A (es)
TN (1) TN2011000182A1 (es)
WO (1) WO2010053883A1 (es)
ZA (1) ZA201103259B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2346990B1 (en) * 2008-11-05 2016-01-06 Merck Sharp & Dohme Corp. Live, attentuated respiratory syncytial virus
WO2013026054A2 (en) * 2011-08-18 2013-02-21 Axella Solutions, Llc Production of infectious rna viruses in yeast
US9463236B2 (en) 2011-08-29 2016-10-11 Tokushima University RSV mucosal vaccine
AU2014214763B2 (en) 2013-02-08 2020-02-27 The Research Foundation For The State University Of New York Attenuation of human respiratory syncytial virus by genome scale codon-pair deoptimization
EP2970981B1 (en) * 2013-03-14 2020-10-28 Emory University Recombinant rsv with silent mutations, vaccines, and methods related thereto
US10369213B2 (en) 2013-10-16 2019-08-06 Merck Sharp & Dohme Corp. Thermostable respiratory synctial virus (RSV) vaccine compositions
WO2015057540A1 (en) 2013-10-16 2015-04-23 Merck Sharp & Dohme Corp. Method of microwave vacuum drying spherical-shaped pellets of biological materials
WO2017030997A1 (en) * 2015-08-14 2017-02-23 Research Institute At Nationwide Children's Hospital Respiratory syncytial virus having altered ns1 protein function and related materials and methods
BR112018008708A2 (pt) 2015-10-29 2018-11-06 Univ Emory rsv quimérico, composições imunogênicas e métodos de uso
WO2018057950A1 (en) 2016-09-23 2018-03-29 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Vaccine candidates for human respiratory syncytial virus (rsv) having attenuated phenotypes
TW202228779A (zh) 2017-03-01 2022-08-01 英商梅迪繆思有限公司 抗rsv單株抗體配製物
KR20200096904A (ko) * 2017-09-15 2020-08-14 오하이오 스테이트 이노베이션 파운데이션 호흡기 세포융합 바이러스(rsv) 감염의 예방을 위한 백신 및 백신의 제조 및 사용 방법

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997038138A1 (en) * 1996-04-04 1997-10-16 The Regents Of The University Of Michigan Attenuated respiratory syncytial virus
JP2002507408A (ja) 1998-03-26 2002-03-12 アメリカン・サイアナミド・カンパニー 麻疹ウイルスもしくはヒト呼吸合胞体ウイルスサブグループｂの弱毒化の原因である突然変異
CN100354425C (zh) 1999-07-09 2007-12-12 美国政府健康及人类服务部 减毒的人－牛嵌合呼吸道合胞病毒疫苗的生产
EP1572108A4 (en) 2002-09-27 2008-09-17 Medimmune Vaccines Inc FUNCTIONAL MUTATIONS OF RSV (RESPIRATORY SYNCYTIAL VIRUS)
CA2520671C (en) * 2003-03-28 2014-03-18 Medimmune Vaccines, Inc. Compositions and methods involving respiratory syncytial virus subgroup b strain 9320
US20100323428A1 (en) * 2007-02-07 2010-12-23 Dnavec Corporation Attenuated minus-stranded rna virus
EP2346990B1 (en) * 2008-11-05 2016-01-06 Merck Sharp & Dohme Corp. Live, attentuated respiratory syncytial virus

Also Published As

Publication number Publication date
TN2011000182A1 (en) 2012-12-17
MX2011004719A (es) 2011-05-31
ZA201103259B (en) 2012-01-25
CO6362047A2 (es) 2012-01-20
US20110212130A1 (en) 2011-09-01
JP2012507302A (ja) 2012-03-29
CL2011000999A1 (es) 2012-07-20
PE20110394A1 (es) 2011-06-22
JP5016731B2 (ja) 2012-09-05
AU2009311287C1 (en) 2015-02-19
WO2010053883A1 (en) 2010-05-14
EP2346990A1 (en) 2011-07-27
AU2009311287B2 (en) 2013-02-07
EP2346990B1 (en) 2016-01-06
CN102272295A (zh) 2011-12-07
RU2011122615A (ru) 2012-12-20
JP2011250798A (ja) 2011-12-15
IL212437A0 (en) 2011-06-30
JP5743794B2 (ja) 2015-07-01
KR20110063863A (ko) 2011-06-14
US9011876B2 (en) 2015-04-21
BRPI0921424A2 (pt) 2016-01-05
AU2009311287A1 (en) 2010-05-14
MA32878B1 (fr) 2011-12-01
CA2742086A1 (en) 2010-05-14

Similar Documents

Publication Publication Date Title
ECSP11011033A (es) Virus sincitial respiratorio vivo atenuado
CY1124742T1 (el) 4'-φθορο-νουκλεοσιδια, 4'-φθορο-νουκλοεοτιδια και αναλογα αυτων για τη θεραπευτικη αγωγη toy hcv
UY32457A (es) Vacuna del virus del dengue inactivado
GT201500005A (es) Composiciones de vacuna para la prevencion contra la infeccion por el virus del dengue
CR20160337A (es) Nuevas heteroarildihidropirimidinas 6-fusionadas para el tratamiento y la profilaxis de la infección por virus de la hepatitis b
CY1117757T1 (el) Τροποποιημενες πρωτεϊνες rsv f και μεθοδοι χρησης τους
UY36465A (es) Compuestos policíclicos de carbamoilpiridona y su uso farmacéutico
CL2013002379A1 (es) Virus del sindrome reproductor y respiratorio porcino (prrsv); procedimiento para la preparacion del prrsv atenuado vivo; vacuna que lo comprende y su procedimiento de preparacion; y procedimiento para inmunizar cerdos contra el sindrome reproductor y respiratorio porcino.
CO6630147A2 (es) Modificador del sabor dulce
EA201270063A1 (ru) Рекомбинантные антигены pcb
PE20151867A1 (es) Polipeptidos f de prefusion del virus sincicial respiratorio (rsv )solubles y estabilizados
BR112014024159A2 (pt) Formulações de vacina oral específicas do local gastrintestinal , ativas no íleo e apêndice.
CY1118399T1 (el) Ενωσεις βενζοφουρανιου για την θεραπεια μολυνσεων ιου ηπατιτιδας c
CL2017001961A1 (es) Vacuna bivalente contra el virus de gripe porcina
SV2011003907A (es) Composiciones antimicrobianas
UY32715A (es) Combinaciones farmacéuticas útiles para el tratamiento del virus de la hepatitis c (vhc), usos y métodos relacionados
UY32758A (es) Composiciones y métodos para el tratamiento de infecciones ópticas, nasales u oftálmicas
CL2019001200A1 (es) Vacuna contra el parvovirus porcino y el virus del síndrome respiratorio reproductivo porcino y métodos de producción de esta.
UY32720A (es) Combinaciones farmaceuticas utiles para el tratamiento del virus de la hepatitis c (vhc), usos y metodos relacionados
UY34420A (es) ?métodos de tratamiento del virus de la hepatitis c con que de gs-7977 y ribavirina, composiciones y usos"
CO2017003840A2 (es) Formulación esterilizada por calor que comprende quitosán y proceso para preparación de la misma
CO7461135A2 (es) Parvovirus porcino 5b, métodos de uso y vacuna
CL2017001595A1 (es) Composiciones de vacuna para el virus del dengue y métodos de uso de las mismas
DOP2015000226A (es) Composiciones y metodos para formulaciones de alfavirus vivos atenuados
MX2016002903A (es) Composiciones inmunogenas de la glicoproteina g de los virus hendra y nipah.